Pacer Advisors Inc. Has $1.65 Million Stock Holdings in Humana Inc. $HUM

Key Points

• Pacer Advisors reduced its Humana stake by 25.7% in the first quarter, selling 3,284 shares and retaining 9,499 shares worth approximately $1.65 million. Institutional investors and hedge funds collectively own 92.38% of Humana.
• Humana reported quarterly earnings of $7.61 per share, beating estimates of $7.27, while revenue rose 26.2% year over year to $40.89 billion, exceeding expectations.
• Shares opened at $384.44, up 4.7%, and analysts maintain a “Moderate Buy” consensus rating with an average price target of $391.87.

Pacer Advisors Inc. reduced its stake in Humana Inc. (NYSE:HUM - Free Report) by 25.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 9,499 shares of the insurance provider's stock after selling 3,284 shares during the period. Pacer Advisors Inc.'s holdings in Humana were worth $1,647,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the company. Montag A & Associates Inc. boosted its holdings in Humana by 1,880.0% in the fourth quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider's stock worth $25,000 after acquiring an additional 94 shares in the last quarter. Fideuram Asset Management Ireland dac acquired a new stake in Humana in the fourth quarter valued at approximately $27,000. Reflection Asset Management bought a new stake in shares of Humana during the fourth quarter valued at approximately $29,000. Global Assets Advisory LLC acquired a new position in shares of Humana during the first quarter worth approximately $38,000. Finally, Larson Financial Group LLC raised its position in shares of Humana by 114.1% during the third quarter. Larson Financial Group LLC now owns 152 shares of the insurance provider's stock worth $40,000 after purchasing an additional 81 shares during the period. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Stock Up 4.7%

Shares of NYSE:HUM opened at $384.44 on Friday. Humana Inc. has a 1 year low of $163.11 and a 1 year high of $428.88. The company has a market capitalization of $46.16 billion, a PE ratio of 36.37, a price-to-earnings-growth ratio of 2.20 and a beta of 0.72. The business has a fifty day moving average price of $377.18 and a two-hundred day moving average price of $271.65. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.74 and a quick ratio of 1.74.

Humana (NYSE:HUM - Get Free Report) last released its earnings results on Wednesday, July 29th. The insurance provider reported $7.61 EPS for the quarter, topping analysts' consensus estimates of $7.27 by $0.34. The company had revenue of $40.89 billion for the quarter, compared to analysts' expectations of $40.58 billion. Humana had a return on equity of 11.20% and a net margin of 0.88%.The business's revenue for the quarter was up 26.2% compared to the same quarter last year. During the same period in the previous year, the business posted $6.27 EPS. Analysts forecast that Humana Inc. will post 9.08 earnings per share for the current year.

Analyst Upgrades and Downgrades

HUM has been the subject of several research reports. Wells Fargo & Company raised shares of Humana from an "equal weight" rating to an "overweight" rating and lifted their price target for the company from $227.00 to $502.00 in a research report on Monday, July 13th. The Goldman Sachs Group raised their price objective on shares of Humana from $158.00 to $195.00 and gave the company a "sell" rating in a research note on Thursday, April 30th. JPMorgan Chase & Co. lifted their price objective on shares of Humana from $214.00 to $316.00 and gave the company a "neutral" rating in a report on Monday, June 8th. Wolfe Research raised shares of Humana from a "peer perform" rating to an "outperform" rating in a research report on Thursday, July 30th. Finally, Oppenheimer reaffirmed an "outperform" rating and issued a $405.00 price target on shares of Humana in a research report on Thursday, July 30th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, fourteen have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Humana presently has a consensus rating of "Moderate Buy" and a consensus target price of $391.87.

Humana Profile

Humana Inc NYSE: HUM is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana's products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source